-
Ligand Down 20% Since August 1; What's The Street Thinking?
Wednesday, August 17, 2016 - 3:16pm | 318Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) hit a 52-week high of $139.79 at the beginning of August. Since then, the stock has been steadily declining and as of Wednesday was trading for less than $109 per share. The stock is now nearly flat since the start of 2016, but still higher by more...
-
Analyst Says Viking Therapeutics Can Quadruple Because Of Its Relationship With Ligand Scientists
Thursday, April 7, 2016 - 2:35pm | 330Read More...Viking Therapeutics Inc (NASDAQ: VKTX) is up 87 percent on Thursday, trading at $2.66. The clinical-stage biopharmaceutical company was incorporated in 2012, and went public in 2015. At just shy of a year old, the metabolic/endocrine solutions company has seen some challenges, and is down 70...
-
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak Guidance
Tuesday, November 18, 2014 - 4:56pm | 220Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported on Tuesday it expects its fiscal 2015 earnings per share to be in a range of $2.14 to $2.18, falling short of the consensus estimate of $2.42. The company expects fiscal 2015 sales to be $81 million to $83 million, also below the consensus...
-
Ligand Enters into Agreement with Proximagen for CXCR4 Target
Friday, September 17, 2010 - 8:12am | 213Read More...Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has transferred exclusive license rights to Proximagen Limited (AIM: PRX) for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous...
